Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 5/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | TRPM8 | Q7Z2W7 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | PTPN22 | Q9Y2R2 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL446371 | 0.87 | ALOX5 (0.53) | PTGESALOX5ALDH1A1LMNAMEN1 | |
| SCHEMBL445377 | 0.87 | PTGES (0.51) | PTGESALOX5ALDH1A1LMNATRPM8 | |
| SCHEMBL444342 | 0.85 | LMNA (0.57) | PTGESALOX5ALDH1A1LMNAKDM4E | |
| SCHEMBL448085 | 0.82 | ALDH1A1 (0.52) | PTGESALOX5ALDH1A1LMNATRPM8 | |
| SCHEMBL447265 | 0.80 | ALDH1A1 (0.43) | ALDH1A1LMNAPOLBMEN1KMT2A | |
| SCHEMBL448503 | 0.78 | PTGES (0.43) | PTGESALOX5ALDH1A1LMNATRPM8 | |
| SCHEMBL446213 | 0.76 | ALDH1A1 (0.46) | ALDH1A1LMNAPOLBMEN1KMT2A | |
| SCHEMBL443448 | 0.76 | GRM2 (0.40) | ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL444612 | 0.74 | CA2 (0.46) | PTGESALOX5ALDH1A1LMNAKMT2A | |
| SCHEMBL444121 | 0.73 | MCL1 (0.49) | PTGESALOX5ALDH1A1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140335517-A1 | DETECTION AND TREATMENT OF SCHIZOPHRENIA | RENASCIENCE CO LTD (JP) | 2014-11-13 | — | — | US | disclosed |
| US-8809329-B2 | Detection and treatment of schizophrenia | TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE (JP) | 2014-08-19 | — | — | US | disclosed |
| EP-2662453-A2 | Detection and treatment of schizophrenia | TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) | 2013-11-13 | — | — | EP | disclosed |
| US-20120065198-A2 | Detection and Treatment of Schizophrenia | TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) | 2012-03-15 | — | — | US | disclosed |
| US-20110028470-A1 | Detection and Treatment of Schizophrenia | TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) | 2011-02-03 | — | — | US | disclosed |
| EP-2189537-A1 | DETECTION AND TREATMENT OF SCHIZOPHRENIA | TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) | 2010-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028470-A1 | Detection and Treatment of Schizophrenia | GLO1, CBR1, AOX1 | PTGES 514/4885ALOX5 359/4885ALDH1A1 240/4885 |
| US-20120065198-A2 | Detection and Treatment of Schizophrenia | GLO1, CBR1, AOX1 | PTGES 514/4885ALOX5 359/4885ALDH1A1 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.